BI-2852
目录号: PL10877 纯度: ≥98%
CAS No. :2375482-51-0
商品编号 规格 价格 会员价 是否有货 数量
PL10877-5mg 5mg ¥4327.27 请登录
PL10877-10mg 10mg ¥6800.00 请登录
PL10877-50mg 50mg ¥20400.00 请登录
PL10877-100mg 100mg ¥35854.55 请登录
PL10877-200mg 200mg 询价 询价
PL10877-500mg 500mg 询价 询价
PL10877-10mM*1mLinDMSO 10mM*1mLinDMSO ¥4920.73 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
BI-2852
英文名称
BI-2852
英文别名
(3~{S})-3-[2-[[[1-[(1-methylimidazol-4-yl)methyl]indol-6-yl]methylamino]methyl]-1~{H}-indol-3-yl]-5-oxidanyl-2,3-dihydroisoindol-1-one;(S)-5-Hydroxy-3-(2-((((1-((1-methyl-1H-imidazol-4-yl)methyl)-1H-indol-6-yl)methyl)amino)methyl)-1H-indol-3-yl)isoindolin-1-one;F0K;(3S)-5-Hydroxy-3-[2-[[[1-[(1-methylimidazol-4-yl)methyl]indol-6-yl]methylamino]methyl]-1H-indol-3-yl;BI-2852
Cas No.
2375482-51-0
分子式
C31H28N6O2
分子量
516.59
包装储存
4°C, stored under nitrogen In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
产品详情
BI-2852 是基于药物结构设计的 switch SI/II 口袋的 KRAS 抑制剂,其通过基于结构的药物设计具有纳摩尔亲和力。 BI-2852 在机理上不同于共价 KRASG12C 抑制剂 (结合 switch II),与活性 KRASG12D 结合强度是与 KRAS wt 的 10 倍 (740 nM vs 7.5 μM)。BI-2852 阻断 GEF,GAP 和效应子与 KRAS 的相互作用,导致下游信号传导的抑制和 KRAS 突变细胞中的抗增殖作用。
生物活性
BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based drug design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRAS inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRAS versus KRAS (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.
性状
Solid
IC50 & Target[1][2]
KRAS(G12C) 450 nM (IC50) KRAS(G12C) 750 nM
体外研究(In Vitro)
BI-2852 (Compound 1) (10 nM-10 μM; 2 hours) shows a dose-dependent pERK modulation and antiproliferative effect at EC50s of 5.8 μM and 6.7 μM in soft agar and low serum conditions in NCI-H358 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, stored under nitrogen In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
参考文献
[1]. Kessler D, et al. Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci U S A. 2019 Aug 6; 116(32):15823-15829.
[2]. Dirk Kessler, et al. Drugging all RAS isoforms with one pocket. FUTURE MEDICINAL CHEMISTRY
溶解度数据
In Vitro: DMSO : 55 mg/mL (106.47 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2